Benjamin L. Palleiko
Independent ChairmanMr. Benjamin L. Palleiko, also known as Ben, serves as Senior Advisor at Frazier Life Sciences Management, LP since September 08, 2026 and joined the firm on September 08, 2026. He served as Chief Executive Officer & Director at KalVista Pharmaceuticals, Inc. from March 7, 2024 to June 2026. At KalVista Pharmaceuticals, Inc., he also served as President, Chief Business Officer & Chief Financial Officer from January 2023 to March 7, 2024, as Chief Business Officer & Chief Financial Officer from March 27, 2019 to January 2023 and as Chief Financial Officer from November 2016 to March 27, 2019 and joined the firm in August 2016. He served as Chief Financial Officer at KalVista Limited, which he joined in August 2016. He is Co-founder of Cielo Therapeutics, Inc and also served as Chief Executive Officer from 2012 to June 2016. He served as Chief Financial Officer, Senior Vice President, Secretary and Treasurer at Ore Holdings, Inc., where he was employed from July 2009 to April 26, 2010. He served as Chief Financial Officer, Senior Vice President of Corporate Development, Company Secretary and Principal Accounting Officer at Penwest Pharmaceuticals Co., where he was employed from June 19, 2006 to January 21, 2009. He is Founder of Intrepid Merchant Partners, LLC, where he served as Principal since March 2006. He served as Director, Head of Life Sciences Investment Banking at Suntrust Robinson Humphrey from March 2003 to March 2006. He served as Vice President, Investment Banking at Robertson Stephens, Inc. from 2000 to 2002. Earlier in his career, he served as a Naval Aviator in the U.S. Navy. Mr. Palleiko has several years' experience as an executive in the life sciences industry, as both a public pharmaceuticals company Chief Financial Officer and as an investment banker. During his tenure at KalVista Pharmaceuticals, the company discovered and developed EKTERLY®, the first oral therapy approved for the treatment of acute hereditary angioedema (HAE) attacks. Mr. Palleiko received a B.A. in Quantitative Economics from Tufts University in 1987 and an M.A. in International Relations and an M.B.A. in Finance from The University of Chicago in 1996. He is Independent Director and Chairman of Frazier Life Sciences Acquisition Corp II from September 2026.
Positions
- Company NameFrazier Life Sciences Acquisition Corp. IIStock CodeFLSCPositionIndependent Chairman
